Document is current
Any future updates will be listed below
-
Authors
Lam, Ka-On
Li, Karen Hoi-Lam
Leung, Roland Ching-Yu
Tang, Vikki
Yau, Thomas https://orcid.org/0000-0002-7114-0305
-
Funding
Funding for this research was provided by:
Taiho Pharma Asia Pacific Pte. Ltd.
- License Information
-
More Information
Article History
Received: 25 September 2024
Accepted: 21 November 2024
First Online: 13 January 2025
Declarations
:
: Karen Hoi-Lam Li has received support for meeting attendance and travel from Taiho Pharma Asia Pacific Pte. Ltd. Ka-On Lam has received speaking honoraria from Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., GSK PLC, Merck & Co. Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Sanofi, and Taiho Pharma Asia Pacific Pte. Ltd. Ka-On Lam has also received meeting and travel support from Merck & Co. Inc. and Taiho Pharma Asia Pacific Pte. Ltd. and advisory board honoraria from Amgen Inc., Astellas Pharma Inc., and GSK PLC. Roland Ching-Yu Leung, Vikki Tang and Thomas Chung-Cheung Yau have no conflicts of interest to disclose. No payment or honoraria have been received by any author for this article.
: The study protocol was reviewed for ethics, science and compliance with the Declaration of Helsinki, ICH GCP guidelines, local regulations, Hospital Authority and university policies. The protocol, encompassing the use of CDARS data from all participating centers, was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster before any data collection occurred (IRB reference number UW 19-460). The requirement for informed consent was waived owing to the anonymous nature of the data.
